13F-HR - Formuepleje A/S (0001801212) (Filer)
Institutional holdings report (13F-HR) filed by Formuepleje A/S.
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Institutional holdings report (13F-HR) filed by Formuepleje A/S.
Institutional holdings report (13F-HR) filed by Formuepleje A/S.
Institutional holdings report (13F-HR) filed by Formuepleje A/S.
Institutional holdings report (13F-HR) filed by Formuepleje A/S.
Institutional holdings report (13F-HR) filed by Formuepleje A/S.
The Bank issued $317 million in debt across 7 series including variable and fixed-rate notes with maturities between 2026 and 2033. The issuance bolsters liquidity and funding for …
CalciMedica announced a 5-for-1 reverse stock split effective after the filing of an amendment to its certificate of incorporation. This move aims to ensure compliance with Nasdaq'…
Faraday Future revealed a three-phase execution roadmap and announced plans to invest $5 billion, aiming to bring its Robot Factory online by year-end. It simultaneously opened nat…
NeuroOne succeeded in procedures combining robotic drug delivery with electrophysiological monitoring, validating a workflow expected to be recognized as revenue this fiscal quarte…
The company regained compliance with Nasdaq's minimum bid price requirement, citing a reverse share split. Market impact is neutral as this is a non-discretionary recovery from a p…
Dolby Laboratories announced that Marc Whitten, a veteran executive, was named President and CEO to succeed Kevin Yeaman, who is retiring after 20 years. The move comes as the audi…
Alpha Modus Holdings entered a Bitcoin-backed private placement to sell 51.6M Class A shares for ~3,170 BTC. Market participants will likely view this alternative asset collaterali…
The company agreed with KEPCO to nearly six-fold increase power capacity for its Korean operations and announced land and facility expansions to annualize 10,000 tons of magnet pro…
Glucotrack will reduce its outstanding shares to approximately 798,144 via a 1-for-15 reverse split, effective at market open on August 31, 2026. This action is necessary to regain…
DFDV resumed buying SOL, acquiring 19,000 at $98.14 average, and outperformed SOL significantly over recent periods, leading SOL digital asset company trading activity.
October's Very Own and its affiliates proposed to sell certain Intellectual Property, Overseas Merchandising, and direct sales assets and equity subsidiaries to Vinco Brands at a c…
MBX Biosciences initiated the Phase 3 oPTimize trial for once-weekly canvuparatide in hypoparathyroidism; the initiative positions the biotech firm to vie for a potential best-in-c…
Hyperliquid Strategies Inc raised $647 million, nearly doubled its HYPE treasury, and finished with a fortress balance sheet of $149.9 million cash while launching a top five valid…
The company filed a Certificate of Change to amend its certificate of incorporation, to increase the number of authorized shares of its common stock.
Parent company Abvc Pharma will distribute a 15% equity stake in BioKey (Cayman) to its shareholders, triggering a spin-off transaction.